Author Page for Yangang Wang

Efficacy and Safety of the Peroxisome Proliferator-Activated Receptor Pan-Agonist Chiglitazar in Patients with Type 2 Diabetes (CMAP): A 24 Week, Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase 3 Superiority Trial

Number of pages: 100 Posted: 21 Aug 2019

Linong Ji, Weihong Song, Hui Fang, Wei Li, Jianlin Geng, Yangang Wang, Lian Guo, Hanqing Cai, Tao Yang, Hongmei Li, Gangyi Yang, Qifu Li, Kuanzhi Liu, Shuying Li, Yanjun Liu, Fuyan Shi, Xinsheng Li, Xin Gao, Haoming Tian, Qiuhe Ji, Qing Su, Zhiguang Zhou, Wenbo Wang, Zunhai Zhou, Xuejun Li, Yancheng Xu, Zhiqiang Ning, Haixiang Cao, Desi Pan, He Yao, Xianping Lu and Wei-Ping Jia

Peking University - Department of Endocrinology and Metabolism, Southern Medical University - Chenzhou No.1 People's Hospital, Tangshan Gongren Hospital, Xuzhou Medical University, Harrison International Peace Hospital, Qingdao University - Affiliated Hospital, China Three Gorges University (CTGU) - College of Medical Science, Jilin University (JLU) - Second Hospital, Jiangsu Province Hospital, China Meitan General Hospital, Chongqing University, Chongqing Medical University - Department of Endocrinology, Hebei Medical University, Tianjin Medical University - General Hospital, Government of the People's Republic of China - 306th Hospital, Baogang Hospital of Inner Mongolia, Cangzhou Central Hospital, Fudan University - Zhongshan Hospital, Sichuan University, Government of the People's Republic of China - Fourth Military Medical University, Shanghai Jiao Tong University (SJTU) - Xinhua Hospital, The Second Xiangya Hospital of Central South University - Key Laboratory of Diabetes Immunology, Peking University, Central South University - Second Xiangya Hospital, Xiamen University - First Affiliated Hospital, School of Economics and Management - Zhongnan Hospital, Chipscreen Biosciences Ltd, Chipscreen Biosciences Ltd, Chipscreen Biosciences Ltd, Chipscreen Biosciences Ltd, Chipscreen Biosciences Ltd and Shanghai Jiao Tong University (SJTU) - Department of Endocrinology and Metabolism

Downloads 40 (627,015)

Abstract:

2.

Insulin Delivery with a Needle-Free Insulin Injector Versus a Conventional Insulin Pen in Chinese Patients with Type 2 Diabetes Mellitus: A 16-Week, Multicenter, Randomized Clinical Trial (the FREE Study)

Number of pages: 30 Posted: 21 Feb 2020

Linong Ji, Leili Gao, Liming Chen, Yangang Wang, Zhongshu Ma, Xingwu Ran, Zilin Sun, Xiangjin Xu, Guixia Wang, Lixin Guo and Zhongyan Shan

Peking University - Department of Endocrinology and Metabolism, Peking University - Department of Endocrinology and Metabolism, Tianjin Medical University - Metabolic Disease Hospital, Qingdao University - Affiliated Hospital, Tianjin Medical University - Department of Endocrinology and Metabolism, Sichuan University - West China Hospital, Southeast University - Department of Endocrinology, Government of the People's Republic of China - Fuzhou General Hospital, Jilin University (JLU) - Department of Endocrinology and Metabolism, Beijing Hospital - National Center of Gerontology, Department of Endocrinology and China Medical University - Department of Endocrinology and Metabolism

Downloads 19 (776,650)

Yangang Wang

Qingdao University - Affiliated Hospital

2

59

0

0

Scholarly Papers (2)

Efficacy and Safety of the Peroxisome Proliferator-Activated Receptor Pan-Agonist Chiglitazar in Patients with Type 2 Diabetes (CMAP): A 24 Week, Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase 3 Superiority Trial

Abstract:

Insulin Delivery with a Needle-Free Insulin Injector Versus a Conventional Insulin Pen in Chinese Patients with Type 2 Diabetes Mellitus: A 16-Week, Multicenter, Randomized Clinical Trial (the FREE Study)

Abstract: